HC Wainwright set a $2.00 target price on Vaxart (NASDAQ:VXRT) in a report released on Wednesday, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts also recently commented on VXRT. Brookline Capital Management began coverage on Vaxart in a report on Thursday, August 15th. They issued a buy rating and a $6.00 price objective on the stock. ValuEngine upgraded Vaxart from a hold rating to a buy rating in a report on Thursday, August 1st.
NASDAQ:VXRT opened at $0.66 on Wednesday. The stock’s 50 day moving average price is $0.69 and its 200 day moving average price is $1.08. Vaxart has a 52 week low of $0.55 and a 52 week high of $7.60. The company has a market capitalization of $10.63 million, a P/E ratio of -0.25 and a beta of 0.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.29 and a current ratio of 2.29.
Vaxart Company Profile
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
See Also: What is a death cross?
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.